Skip to content
lifestyle.realie.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
IDEAYA Biosciences, Inc.
IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants
June 8, 2026
IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
June 8, 2026
IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer
June 3, 2026
IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO
June 1, 2026
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 29, 2026
IDEAYA Biosciences Announces Participation at the 2026 Jefferies Global Healthcare Conference
May 26, 2026
IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
May 21, 2026
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 20, 2026
IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program
May 20, 2026
IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma
April 21, 2026
1
2
3
Next Page
→